共 70 条
[1]
Hansen L(2013)A health economic analysis of osteoporotic fractures: who carries the burden? Arch Osteoporos 8 126-278
[2]
Mathiesen AS(2001)Economic implications of hip fracture: health service use, institutional care and cost in Canada Osteoporos Int 12 271-1650
[3]
Vestergaard P(2009)Excess mortality following hip fracture: a systematic epidemiological review Osteoporos Int 20 1633-413
[4]
Ehlers LH(1990)Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis J Endocrinol Investig 13 407-29
[5]
Petersen KD(2013)Excess mortality attributable to hip-fracture: a relative survival analysis Bone 56 23-2046
[6]
Wiktorowicz ME(2012)Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention J Bone Miner Res 27 2039-2065
[7]
Goeree R(2011)Coordinator-based systems for secondary prevention in fragility fracture patients Osteoporos Int 22 2051-149
[8]
Papaioannou A(2016)Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects Osteoporos Int 28 139-380
[9]
Adachi JD(2010)Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006 Osteoporos Int 21 373-397
[10]
Papadimitropoulos E(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-76